WINDSOR, ON / ACCESSWIRE / May 19, 2015 / The Wealthy Biotech Trader, an Investment Newsletter focused on showing everyday Investors new opportunities in rapidly growing, little-known, Biotech stocks making news and subsequent market moves.
The development of new cancer treatments is always ongoing and investors should monitor for emerging ideas and stocks. Companies like Propanc (OTC: PPCH), Cerulean Pharma (NASDAQ: CERU), Peregrine Pharma (NASDAQ: PPHM), and Verastem (NASDAQ: VSTM) could all move higher as their treatments potentially pass clinical testing thresholds. If investors can identify a few potential winners early on in the development process, returns could be substantial. Out of these four mentioned companies we believe Propanc (OTC: PPCH) is the most overlooked and presents investors with greatest potential return on investment, here's why:
Propanc, while small, has had a steady stream of positive news over the past three months. For Propanc Health Group, the share price has increased by more than 3,200%+ as a result of these new developments. In April, the company was featured in the NY Times Sunday Magazine in its feature 'Health Essentials: Cancer Prevention and Treatment'. The article featured the company's CEO and Co-Founder James Nathanielsz's perspective on the new developments with the company's technology and plans to commercialize it.
Propanc is a developmental stage healthcare company that is primarily focused on developing cancer treatments for pancreatic and colorectal cancer. The company has created an anti-cancer formulation that controls spreading of tumors throughout the body. The formulation consists of proenzymes (inactive precursors to enzymes) designed to fight or prevent cancer when activated at the tumor site. There are various oral enzyme preparations to support cancer patients, but none are yet clinically proven. The company is presently completing animal trials and then will undertake human trials before its primary products are marketable in the United States. However, the company may seek to license its technology to a major Pharma or Biotech company once proof of concept in cancer patients
FURTHER DEVELOPMENTS AT PROPANC
In March, the company announced it had entered the second stage of its POP1 research program with the University of Jaen and University of Granada, Spain. The research program is investigating the anti-cancer effects as well as the cellular mechanisms of proenzymes in the treatment of cancer. The study could help identify additional drugs beyond its core product, PRP. The company also has a joint research partnership with Bath University. It filed a joint patent with Bath University where it received the commercial rights. The team put together by Dr. Macarena Peran has pulled together these research institutions to continue to collaborate with the goal of finding additional compounds that complement existing cancer treatments.
Earlier this month the company reported that its first set of results were in from animal studies. The studies showed no adverse signs from using PRP at higher doses in mice when administered by intravenous (I.V) injection. The dose is more than double the human equivalent administered to late stage cancer patients for compassionate use by Dr Julian Kenyon (Propanc's Co-Founder and Chief Scientific Officer). This is a key step in more widespread studies. PRP was administered in the study by I.V. injection to ensure 100% was transferred to the bloodstream. Previously, it was administered via suppository where it likely has a much lower, uncertain absorption rate in the blood, but where outpatients could receive their once daily treatment at home for compassionate use.
All this supports the drugs' move towards human trials with an I.V. injection formulation. For shareholders and the company, this is positive news. It continues to advance PRP towards human trials. At each step, positive results could drive the stock higher as the likelihood of the future revenue stream improves.
REPAYMENT OF CONVERTIBLE DEBT, POSITIVE FOR SHAREHOLDERS
Propanc announced it had repaid convertible debt of $100,236.50 to KBM Worldwide, Inc. It is also looking to repay any other debts due beyond 90 days. This will minimize shareholder dilutions and is a positive sign from management. It indicated that management is positive about its current and future cash position.
STUDY OF PRP EFFECTS ON CANCER STEM CELLS
In this chain of positive announcements, Propanc along with its partner, University of Jaen, announced that it will study the effects of PRP on cancer stem cells. In prior studies, PRP induced differentiation of tumor cells, and it is testing the hypothesis that the formulation will induce differentiation on cancer stem cells as well. Cancer stem cells remain in a latent state and are not killed by radiation or chemotherapy. While other cancer cells may have been completely eliminated, the presence of these cancer stem cells can cause a relapse and metastasis.
OTHERS TARGETING CANCER TREATMENTS
A treatment that can impact these stem cells is in high demand. Verastem (NASDAQ: VSTM) is another company that focuses on this part of the market. It is developing small molecule drugs that target cancer stem cells. It has treatments that are currently in clinical trials that investors should also follow for new developments.
Cerulean Pharma (NASDAQ: CERU) is another company that is in the clinical stages of testing treatments. Like Verastem and Propanc, it is working in the field of oncology but also in the treatment of other diseases. The company develops nano pharmaceutical product candidates and has products in Phase I and Phase II clinical trials.
Peregrine Pharma (NASDAQ: PPHM) is another company investors should follow that is developing treatments for cancer. It is seeking to use monoclonal antibodies for the treatment and diagnosis of cancer. Its leading immunotherapy product, bavituximab, is in the late stages of clinical trials.
All of these companies, Propanc (OTC: PPCH), Cerulean Pharma (NASDAQ: CERU), Peregrine Pharma (NASDAQ: PPHM), and Verastem (NASDAQ: VSTM) are seeking to develop cancer treatments. Each company is working through various stages of clinical trials and as the trials advance, the share prices could follow. In addition to these positive results, shareholders could find earlier than expected payouts; large pharmaceutical companies are constantly acquiring promising new treatments and the companies that develop them. THIS COULD ALSO ACT AS A CATALYST TO MOVE THE SHARES OF THESE STOCKS HIGHER.
The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.
GET BREAKING NEWS FROM US:
Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.
The Wealthy Biotech Trader's parent company is and will be compensated roughly $5,000 per month by Propanc Health Group. The Wealthy Biotech Trader's controlling parent company has also been compensated $60,000 by Propanc Health Group in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.
Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.
SOURCE: The Wealthy Biotech Trader
